Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 14:14:1228895.
doi: 10.3389/fphar.2023.1228895. eCollection 2023.

Recent advances in the study of anesthesia-and analgesia-related mechanisms of S-ketamine

Affiliations
Review

Recent advances in the study of anesthesia-and analgesia-related mechanisms of S-ketamine

Jian-Shun Zhou et al. Front Pharmacol. .

Abstract

Ketamine is a racemic mixture of equal amounts of R-ketamine and S-ketamine and is well known to anesthesiologists for its unique dissociative anesthetic properties. The pharmacological properties of ketamine, namely, its sympathetic excitation, mild respiratory depression, and potent analgesia, are still highly valued in its use as an anesthetic for some patients. In particular, since its advent, S-ketamine has been widely used as an anesthetic in many countries due to its increased affinity for NMDA receptors and its enhanced anesthetic and analgesic effects. However, the anesthetic and analgesic mechanisms of S-ketamine are not fully understood. In addition to antagonizing NMDA receptors, a variety of other receptors or channels may be involved, but there are no relevant mechanistic summaries in the literature. Therefore, the purpose of this paper is to review the mechanisms of action of S-ketamine on relevant receptors and systems in the body that result in its pharmacological properties, such as anesthesia and analgesia, with the aim of providing a reference for its clinical applications and research.

Keywords: AMPA; NMDA; S-ketamine; analgesia; anesthesia; ketamine; opioid receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Domain organization of NMDA receptor subunits. The GluN1-GluN2A heterodimer is shown on the left, and the GluN1-GluN2B heterodimer is shown on the right. Blue indicates the GluN1 subunit, purple indicates the GluN2A subunit, yellow indicates the GluN2B subunit, and the green receptor indicated by the dotted line is the binding site of S-ketamine.
FIGURE 2
FIGURE 2
Schematic diagram of NMDA receptor structure. The green receptor indicated by the dotted line is the binding site of S-ketamine. The three PDZ structural domains linked below the GluN2B subunit form PSD-95, which can interact with nNOS to regulate the production of NO.
FIGURE 3
FIGURE 3
Simple diagram of S-ketamine producing anesthesia and analgesia. S-ketamine acts on GluN1-GluN2A and GluN1-GluN2B subunits and blocks NMDA receptor channels, which is the basis of S-ketamine-induced loss of consciousness and analgesia. Moreover, inhibition of presynaptic NMDA receptor channels can lead to deinhibition of glutamatergic neuronal activity and indirect activation of AMPA receptors.
FIGURE 4
FIGURE 4
S-Ketamine produces analgesia by other pathways. S-ketamine excites sympathetic nerves, leading to the release of NA. NA both activates the descending analgesic pathway, which produces analgesic effects, and binds to adrenoceptors (ARs), promoting the release of opioids (OPs) from immune cells. Both S-ketamine and OP can bind to the opioid receptor (OR), decreasing intracellular cAMP levels and thus blocking Ca2+ channels and TRPV1 channels to produce an analgesic effect.

Similar articles

Cited by

References

    1. Argiriadou H., Himmelseher S., Papagiannopoulou P., Georgiou M., Kanakoudis F., Giala M., et al. (2004). Improvement of pain treatment after major abdominal surgery by intravenous S+-ketamine. Anesth. Analg. 98 (5), 1413–1418. 10.1213/01.ane.0000111204.31815.2d - DOI - PubMed
    1. Bai N., Hayashi H., Aida T., Namekata K., Harada T., Mishina M., et al. (2013). Dock3 interaction with a glutamate-receptor NR2D subunit protects neurons from excitotoxicity. Mol. Brain 6, 22. 10.1186/1756-6606-6-22 - DOI - PMC - PubMed
    1. Bieber M., Schwerin S., Kreuzer M., Klug C., Henzler M., Schneider G., et al. (2022). s-ketamine enhances thalamocortical and corticocortical synaptic transmission in acute murine brain slices via increased AMPA-receptor-mediated pathways. Front. Syst. Neurosci. 16, 1044536. 10.3389/fnsys.2022.1044536 - DOI - PMC - PubMed
    1. Bornemann-Cimenti H., Wejbora M., Michaeli K., Edler A., Sandner-Kiesling A. (2016). The effects of minimal-dose versus low-dose S-ketamine on opioid consumption, hyperalgesia, and postoperative delirium: A triple-blinded, randomized, active- and placebo-controlled clinical trial. Minerva Anestesiol. 82 (10), 1069–1076. - PubMed
    1. Bosma R. L., Cheng J. C., Rogachov A., Kim J. A., Hemington K. S., Osborne N. R., et al. (2018). Brain dynamics and temporal summation of pain predicts neuropathic pain relief from ketamine infusion. Anesthesiology 129 (5), 1015–1024. 10.1097/aln.0000000000002417 - DOI - PubMed

LinkOut - more resources